VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

PHR.US

26.11

+3.08%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

PHR.US

26.11

+3.08%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

PHR.US

26.11

+3.08%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

PHR.US

26.11

+3.08%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

PHR.US

26.11

+3.08%↑

Search

Medtronic PLC

Fechado

SetorSaúde

88.96 0.59

Visão Geral

Variação de preço das ações

24h

Atual

Mín

87.4

Máximo

88.97

Indicadores-chave

By Trading Economics

Rendimento

32M

1.3B

Vendas

-111M

8.3B

P/E

Médio do Setor

27.396

63.778

EPS

1.39

Rendimento de Dividendos

3.12

Margem de lucro

15.798

Funcionários

95,000

EBITDA

-40M

2.4B

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+8.94% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

3.12%

2.39%

Próximos Ganhos

22 de mai. de 2025

Próxima data de dividendos

11 de abr. de 2025

Próxima data de ex-dividendo

27 de jun. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-5.4B

115B

Abertura anterior

88.37

Fecho anterior

88.96

Sentimento de Notícias

By Acuity

30%

70%

94 / 386 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Medtronic PLC Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

18 de fev. de 2025, 12:24 UTC

Ganhos

Medtronic 3Q Revenue Rises on Strength in Cardiovascular, Neuroscience

19 de nov. de 2024, 12:27 UTC

Ganhos

Medtronic Narrows Fiscal Year Guidance as 2Q Tops Views

27 de fev. de 2025, 10:30 UTC

Principais Notícias

Squeezed by Strong Dollar, Companies Try to Neutralize Currency Swings -- WSJ

18 de fev. de 2025, 11:47 UTC

Ganhos

Medtronic: Will Accelerate Top-, Bottom-Line Growth in 4Q >MDT

18 de fev. de 2025, 11:46 UTC

Ganhos

Medtronic Still Sees FY25 Organic Revenue Growth 4.75%-5% >MDT

18 de fev. de 2025, 11:45 UTC

Ganhos

Medtronic 3Q Adj EPS $1.39 >MDT

18 de fev. de 2025, 11:45 UTC

Ganhos

Medtronic 3Q Neuroscience Portfolio Rev $2.46B >MDT

18 de fev. de 2025, 11:45 UTC

Ganhos

Medtronic 3Q Net $1.29B >MDT

18 de fev. de 2025, 11:45 UTC

Ganhos

Medtronic 3Q Diabetes Rev $694M >MDT

18 de fev. de 2025, 11:45 UTC

Ganhos

Medtronic 3Q Medical Surgical Portfolio Rev $2.07B >MDT

18 de fev. de 2025, 11:45 UTC

Ganhos

Medtronic 3Q Cardiovascular Portfolio Rev $3.04B >MDT

18 de fev. de 2025, 11:45 UTC

Ganhos

Medtronic 3Q Organic Revenue Up 4.1% >MDT

18 de fev. de 2025, 11:45 UTC

Ganhos

Medtronic 3Q EPS $1.01 >MDT

18 de fev. de 2025, 11:45 UTC

Ganhos

Medtronic Sees FY Adj EPS $5.44-Adj EPS $5.50 >MDT

18 de fev. de 2025, 11:45 UTC

Ganhos

Medtronic 3Q Sales $8.29B >MDT

18 de fev. de 2025, 10:01 UTC

Ganhos
Ações em Alta

Stocks to Watch Tuesday: Intel, Baidu, Constellation Brands -- WSJ

21 de jan. de 2025, 19:15 UTC

Principais Notícias

Medtronic Hires CFO From Renault -- Update

21 de jan. de 2025, 12:17 UTC

Principais Notícias

Medtronic Hires CFO From Renault

19 de nov. de 2024, 12:12 UTC

Ganhos

Medtronic Narrows FY Guidance as 2Q Tops Views

19 de nov. de 2024, 11:46 UTC

Ganhos

Medtronic Sees High-Single-Digit Adjusted EPS Growth in 2nd Half of FY25 >MDT

19 de nov. de 2024, 11:46 UTC

Ganhos

Medtronic Narrows FY25 Organic Rev Growth View to 4.75%-5% From 4.5%-5% >MDT

19 de nov. de 2024, 11:45 UTC

Ganhos

Medtronic 2Q Medical Surgical Portfolio Rev $2.13B >MDT

19 de nov. de 2024, 11:45 UTC

Ganhos

Medtronic 2Q Adj EPS $1.26 >MDT

19 de nov. de 2024, 11:45 UTC

Ganhos

Medtronic 2Q Diabetes Rev $686M >MDT

19 de nov. de 2024, 11:45 UTC

Ganhos

Medtronic 2Q Neuroscience Portfolio Rev $2.45B >MDT

19 de nov. de 2024, 11:45 UTC

Ganhos

Medtronic 2Q Net $1.27B >MDT

19 de nov. de 2024, 11:45 UTC

Ganhos

Medtronic 2Q Organic Revenue Up 5.0% >MDT

19 de nov. de 2024, 11:45 UTC

Ganhos

Medtronic 2Q Cardiovascular Portfolio Rev $3.1B >MDT

19 de nov. de 2024, 11:45 UTC

Ganhos

Medtronic Sees FY Adj EPS $5.44-Adj EPS $5.50 >MDT

19 de nov. de 2024, 11:45 UTC

Ganhos

Medtronic 2Q Sales $8.4B >MDT

Comparação entre Pares

Variação de preço

Medtronic PLC Previsão

Preço-alvo

By TipRanks

8.94% parte superior

Previsão para 12 meses

Média 96.4 USD  8.94%

Máximo 109 USD

Mínimo 85 USD

Com base em 19 analistas de Wall Street que oferecem metas de preço de 12 meses para Medtronic PLC - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

19 ratings

9

Comprar

9

Manter

1

Vender

Pontuação Técnica

By Trading Central

88.02 / 90.29Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Weak Bullish Evidence

Sentimento

By Acuity

94 / 386 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.